

Minutes of the Lancashire and South Cumbria Medicines Management Group Meeting
Thursday 13th March 2025 (via Microsoft Teams)

Name	Role and organisation	Nov-24	Dec-24	Jan-25	Feb-25	Mar-25	Apr-25
Andy White (AW)	ICB Chief Pharmacist (Chair)	✓	✓		✓	✓	
Trust senior medical representation from the following trusts							
Dr Hanadi Sari-Kouzel (DHSK)	Blackpool Teaching Hospitals	✓	✓		✓	✓	
	University Hospitals of Morecambe Bay						
	Lancashire Teaching Hospitals						
Dr Shenaz Ramtoola (DSR)	East Lancashire Teaching Hospitals	Deputy	✓		✓	Deputy	
	Lancashire and South Cumbria Foundation Trust						
Trust senior pharmacist representation from the following trusts							
James Baker (JB)	Blackpool Teaching Hospitals	✓	✓		✓	✓	
Andrea Scott (AS) (Nima Herlekar (NH) or Jenny Oakley temporarily attending (JO))	University Hospitals of Morecambe Bay	✓	NH		JO attending	JO attending	
David Jones (DJ)	Lancashire Teaching Hospitals	✓	✓		✓	✓	
Ana Batista (AB)	East Lancashire Teaching Hospitals	✓	✓		✓	Apol	
Dorna Ghashghaei (DG)	Lancashire and South Cumbria Foundation Trust	SR	SR			✓	
Primary care Integrated Care Partnership senior medical representation							
To be recruited	Fylde Coast						
To be recruited	Central						
To be recruited	Morecambe Bay						
To be recruited	Pennine Lancashire						
Primary care Integrated Care Partnership senior pharmacist representation							
Melanie Preston (MP)	Fylde Coast	✓	✓		Deputy	Deputy	
Clare Moss (CM)	Central	Apol	Apol		✓	✓	
Lisa Rogan (LR)	Pennine Lancashire	Apol	Apol		Apol	Deputy	
Faye Prescott (FP)	Morecambe Bay	✓	✓		✓	✓	
Other roles							

Nicola Baxter (NB)	ICB Lead for Medicines Governance and Medicines Safety	✓	✓			Apol	Apol	
	ICB Senior Commissioning Manager							
Lucy Dickinson (LD)	ICB Finance Representative	✓	✓			✓	✓	
	Provider finance representative							
Roger Scott (RS)	Local Medical Committee Representation	✓	✓			Apol		
Mubasher Ali (MA)	Community Pharmacy LSC	✓	✓			✓	Apol	
Emma Coupe (EC)	Assistant Director of Pharmacy Clinical Services EHTL		✓				✓	
IN ATTENDANCE:								
Brent Horrell (BH)	CSU Head of Meds Commissioning	✓	✓			Apol	✓	
Daivd Prayle (DP)	CSU Senior Meds Commissioning Pharmacist	✓	✓			✓	✓	
Adam Grainger (AGR)	CSU Senior Meds Performance Pharmacist	Apol	Apol			✓	Apol	
Jill Gray (JG)	CSU Meds Commissioning Pharmacist	✓						
Emily Broadhurst (EB)	Medicines Optimisation Administrator (minutes)	Deputy	Deputy			✓	✓	

As the Jan 25 meeting was due to fall close to the Christmas break it was cancelled and the February meeting brought forward by a week

Key

Present	✓
Apologies received	Apol
Apologies received / Deputy Attended	Deputy
Absent	Absent

	SUMMARY OF DISCUSSION	ACTION
2025/023	<p>Welcome & apologies for absence</p> <p>Apologies were received from Andrea Scott with Jenny Oakly attending, Ana Batista, Kam Mom, Mubasha Ali, Lisa Rogan with Laila Dedat attending, Nicola Baxter, Adam Grainger, Shenaz Ramtoola with Sebastian Dominic attending and Melanie Preston with Rukaiya Chand attending. Sonia Ramdour has stepped down from her position at this meeting and Dorna Ghashghaei will become the new Pharmacy representative for LSCFT with Matthew Ling also attending as deputy.</p>	
	<p>Declaration of any other urgent business</p>	

2025/024	None raised.	
2025/025	Declarations of interest (DOI) None.	
2025/026	Minutes and action sheet from the last meeting 6th February 2025 The Minutes were approved and will be uploaded to the website.	
2025/027	Matters arising (not on the agenda): AW raised the ICB has approved in principle the GP local enhanced services which includes shared care. This will go live from the 1 st of May 2025 provisionally if approved by the board. Comms will be sent out detailing expectations.	
NEW MEDICINES REVIEWS		
2025/028	Dry Mouth Products – Moderate A request that came from formulary working group to increase range of Dry Mouth Products, effectively incorporating a number of items from East Lancashire legacy formulary. Additional proposed items were listed in the document sent to the group. Glandosane was raised as being discontinued so will be removed from the list. The additional items were agreed as there are no cost pressure, additional wording on their intended use to be included in the formulary. Action Add items to formulary with additional wording on their intended use.	DP
2025/029	New Medicines Review Workplan: DP went through the workplan for discussion. The plan was agreed, and the following were agreed to be removed from prioritisation. Acarizax to be removed as was approved by NICE. Itulazax due for a review by NICE in the Autumn, remove from workplan. Fezolinetant (Veoza [®]) (HRT) is due for review by NICE, remove. The following items were raised for additional action. Clarity on when and where Actimorph would be useful. Dorna Ghashaei to link in with DP around Rivastigmine twice weekly patches to expedite the process. Denogest to be de-prioritised. DP to check the commissioning in relation to Botulinum Toxin for anal fissure. Also, as Botox can be used in a large number of indications, it may be better to review and adopt what has been developed in Manchester as opposed to developing from scratch. Actions DP to get clarity on when and where Actimorph would be used.	DP DP/DG

	DP to link in with Dorna Ghashaei around Rivastigmine twice weekly patches. DP to look into commissioning for Botulinum Toxin for anal fissure.	DP
2025/030	New NICE Technology Appraisal Guidance for Medicines February 2025 None for discussion as all were NHSE commissioned. They will be uploaded onto the website once the commissioning information has been received.	
FORMULARY UPDATES		
2025/031	Formulary update: AW added that the formulary needs to be rationalised and only items really needed should be added due to current cost pressures. Due to LSCMMG website closing down, the work on formulary will slow down while the hub team work to transfer all information to NetFormulary. From April 1 st if someone goes to the LSCMMG website they will be redirected to the home page of NetFormulary. Comms are due to be sent around for information. AW added to members to ensure local formularies are turned off and people should be directed to NetFormulary. He again thanked the team for their work on formulary.	
2025/032	Formulary Changes since last LSCMMG The list of changes was sent around to the group for information.	
GUIDELINES and INFORMATION LEAFLETS		
2025/033	Lithium Shared Care - Update This was brought due to a coroner's review, where a patient had not been diagnosed with Nephrogenic Diabetes Insipidus. This is a known concern with patients on Lithium, however, is not mentioned in NICE nor the BNF and as such is not included in the shared care. At the request of the coroner AGR and SR worked to implement changes to the document to highlight the risks. The group were asked to approve the document. The document was approved, it was also agreed that LSCMMG would support SR in raising the concerns with NICE and the BNF if required. Action The updated shared care was approved and will be uploaded to the LSCMMG website. DG to link in with SR around if further support is needed for NICE and BNF.	AGR DG
2025/034	Psoriasis Pathway - Update Second update for the pathway to include as requested a position in the flow chart for the small molecule drugs which were previously just listed as additional options for separate use to the high cost biologic drugs,	

	<p>alongside some other small changes. However it was not possible to agree with specialists where the molecule drugs would sit within the flow chart, so they are now in a box along side the flow chart.</p> <p>The group discussed and the role of the small molecules needs to be more clear and was requested to be taken back for more discussions as to where they should sit.</p> <p>Action</p> <p>DP to take it back for further discussion on where small molecules need to sit within the pathway.</p>	DP
2025/035	<p>Palliative Care Clinical Practice Summary Update</p> <p>Most recent document was sent to the group on Monday due to additional queries. Although there is a lot of changes the majority are minor tweaks to what was already there.</p> <p>The document was approved, and AW thanked the specialist group for their work on this.</p> <p>Action</p> <p>The updated document to be loaded onto the LSCMMG website.</p>	
2025/036	<p>Position statement for biological agents for treating Juvenile Idiopathic Arthritis in adult patients – Update</p> <p>This position statement was updated by the Rheumatology Alliance, DP has outlined the changes in a separate paper. New NICE TA's have been added, new NHSE commissioning has been included, and the document has been tidied up.</p> <p>After a short discussion this was approved.</p> <p>Action</p> <p>The updated document to be loaded onto the LSCMMG website.</p>	
2025/037	<p>Pathways and Guidance workplan:</p> <p>There was nothing new or major for discussion today regarding the work plan. It was raised that currently the Ophthalmology Macular pathway is due in April, however relating to earlier discussions in the meeting it is now very unlikely to come to April's meeting. It was highlighted that AW was to link into the ICB Medical Director to convene a meeting.</p> <p>It was queried about the high strength Fentanyl patches pathway, and if it was in fact relating to reducing the use of them opposed to endorsing them. It was confirmed that was the case.</p>	
NATIONAL DECISIONS FOR IMPLEMENTATION		
2025/038	<p>New NHS England Medicines Commissioning Policies February 2025</p> <p>Nothing to discuss.</p>	
2025/039	<p>Regional Medicines Optimisation Committees – Outputs February 2025</p> <p>Nothing to discuss.</p> <p>It was raised if anyone had anything to put for discussion at the next local</p>	

	<p>RMOC. AW added he has raised the issue around inconsistent RAG positions and the possibility of getting things more aligned. BH raised that there were also APC collaborative discussions on this, Manchester are due to update their paediatric formulary and it was raised then about consistency as well. Other members raised the need for alignment, and the need for a statement in line with the out of area prescribing documents which would highlight the need to work within agreed shared care documents where available, even if the patient is being seen out of area.</p> <p>Action</p> <p>A statement highlighting the need to work within agreed shared care documents where available, even if the patient is being seen out of area to be developed for inclusion in the formulary.</p>	
2025/040	<p>Evidence Reviews Published by SMC or AWMSG February 2025</p> <p>Nothing to discuss.</p>	
ITEMS FOR INFORMATION		
2025/041	<p>LSCMMG Cost Pressures Log</p> <p>This will be circulated with the minutes from today's meeting.</p>	
<p>DATE AND TIME OF NEXT MEETING</p> <p>The next meeting will take place on</p> <p>Thursday 10th April 2025</p> <p>9.30 – 11.30</p> <p>Microsoft Teams</p>		